Ani Pharmaceuticals (ANIP) Depreciation & Amortization (CF): 2009-2024
Historic Depreciation & Amortization (CF) for Ani Pharmaceuticals (ANIP) over the last 16 years, with Dec 2024 value amounting to $67.7 million.
- Ani Pharmaceuticals' Depreciation & Amortization (CF) rose 43.71% to $22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.4 million, marking a year-over-year increase of 51.52%. This contributed to the annual value of $67.7 million for FY2024, which is 13.28% up from last year.
- Ani Pharmaceuticals' Depreciation & Amortization (CF) amounted to $67.7 million in FY2024, which was up 13.28% from $59.8 million recorded in FY2023.
- Ani Pharmaceuticals' Depreciation & Amortization (CF)'s 5-year high stood at $67.7 million during FY2024, with a 5-year trough of $44.6 million in FY2020.
- Over the past 3 years, Ani Pharmaceuticals' median Depreciation & Amortization (CF) value was $59.8 million (recorded in 2023), while the average stood at $62.4 million.
- Data for Ani Pharmaceuticals' Depreciation & Amortization (CF) shows a peak YoY climbed of 26.24% (in 2022) over the last 5 years.
- Ani Pharmaceuticals' Depreciation & Amortization (CF) (Yearly) stood at $44.6 million in 2020, then rose by 5.86% to $47.3 million in 2021, then increased by 26.24% to $59.7 million in 2022, then climbed by 0.23% to $59.8 million in 2023, then rose by 13.28% to $67.7 million in 2024.